Abeona Therapeutics
About Abeona Therapeutics
Abeona Therapeutics is a publicly listed company based in New York (United States) founded in 1974, and was acquired by PlasmaTech Biopharmaceuticals in May 2015. Cell and gene therapies for rare diseases are developed. The company has 136 employees. Abeona Therapeutics offers products and services including pz-cel and ABO-50X. Its focus areas include Life Sciences, Genomics, Applied Genomics and Clinical Genomics. Its competitors include Moderna, BridgeBio and Spark Therapeutics; 3 of its 3 listed competitors have raised funding.
Company details
Abeona Therapeutics was founded in 1974 and is headquartered in New York, United States. Focus is placed on developing cell and gene therapies to address rare diseases. The lead product candidate, EB-101, is designed for Recessive Dystrophic Epidermolysis Bullosa (RDEB). Additional candidates, such as ABO-102 for Sanfilippo Syndrome and ABO-50X for retinal diseases, are under development. Next-generation AAV capsids are also created for broader gene therapy applications.
- Headquarters New York, United States
- Employees 136
- Stage Acquired
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Website abeonatherapeutics.com
- Social LinkedIn X Facebook
- Acquired by PlasmaTech Biopharmaceuticals (May 2015)
- Legal Name Abeona Therapeutics Inc.
- Annual Revenue$5.82 M (USD)as on Dec 31, 2025
- Net Profit$71.18 M (USD)as on Dec 31, 2025
- EBITDA-$85.89 M (USD)-40.1as on Dec 31, 2025
- Latest Funding Round$25M (USD), Post-IPO
Jul 2023
- InvestorsPerceptive Advisors
& 13 more
- Employee Count136
- Acquired byPlasmaTech Biopharmaceuticals
(May 2015)
Products & Services of Abeona Therapeutics
Abeona Therapeutics offers a comprehensive portfolio of products and services, including pz-cel and ABO-50X.
Autologous gene-corrected epidermal sheets for epidermolysis bullosa
Potential treatment for genetic eye disorders through therapy development
Funding Insights of Abeona Therapeutics
- Total Rounds 6
- Last Round Post-IPO — $25M
- Investors Count 13
All 6 funding rounds of Abeona Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2023 | $25M | Post-IPO | – | – | – |
| Nov 2022 | $35M | Post-IPO | – | – | |
| Apr 2022 | $25M | Post-IPO | – | – | – |
| Jul 2015 | $8.5M | Post-IPO | – | – | |
| Nov 2014 | $3.61M | Post-IPO | – | – | |
| Dec 2013 | Post-IPO | – | – |
14 investors in total: 14 institutional.
Investors in Abeona Therapeutics
Abeona Therapeutics has secured backing from 14 investors, including institutional and venture fund investors. Prominent investors backing the company include Perceptive Advisors, Adage Capital Management and Armistice Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Healthcare ecosystem is supported through investment and innovation by Deerfield. | deerfield.com | New York, United States | ||
Health-tech companies are targeted for venture capital investments. | 1999 | perceptivelife.com | New York, United States | |
Offers investment management and secure information access to clients and partners. | 2001 | adagecapital.com | Boston, United States | |
Global hedge fund managing long/short investments in health care and consumer sectors. | 2012 | armisticecapital.com | New York, United States | |
| ecor1cap.com | ||||
Fundamentally-driven firm investing in micro-cap stocks with long and short strategies. | 2004 | nantahalapartners.com | New Canaan, United States | |
| curesff.org | ||||
Non-profit organization funding research and awareness for rare genetic diseases. | 2008 | teamsanfilippo.org | Ronkonkoma, United States | |
Non-profit organization aiding families with MPS and ML through research and support programs. | 1975 | mpssociety.org | Durham, United States | |
| abbygracefoundation.org |
Investor details for Abeona Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Abeona Therapeutics
52 people are tracked at Abeona Therapeutics (23 in leadership, 10 in board & advisors, 19 in team); the tracked headcount is 136.
| Name | Role | Group |
|---|---|---|
Heather Stitely | Executive Director, Account Management | Leadership |
Todd Weatherbie | Director of Information Technology | Leadership |
Erika Nies | Director of Finance | Leadership |
Curtis Bordwell | Associate Director | Leadership |
Madhav Vasanthavada | VP, Business Development | Leadership |
Greg Gin | VP, Investor Relations & Corporate Communications | Leadership |
Brian Kevany | VP, CTO & Head of Research | Leadership |
Alison Hardgrove | VP, Human Resources | Leadership |
Joseph Vazzano | CFO | Leadership |
Vishwas Seshadri | CEO & Director | Leadership |
Maggie C. | Marketing Director | Leadership |
Michael Wu | Head Of Marketing | Leadership |
Angela Iheanacho | Senior Director Clinical Operations | Leadership |
Ben Willis | Director-product Specialist | Leadership |
Amanda Moore | VP, Program Leadership & Clinical Operations | Leadership |
Matthew Blackburn | Director | Leadership |
Paul Wille | Director Of Product Development | Leadership |
Aaron Cardinal | Validation Director | Leadership |
Shriya Bhushan | Vp, Marketing & Sales | Leadership |
Clarisse Benne- Rogat | Director, Process Development | Leadership |
32 more people are available in the full profile.
Complete people profiles for Abeona Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Abeona Therapeutics
Abeona Therapeutics is a publicly listed company on the NASDAQ with ticker symbol ABEO in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date19 Sep 1980
- Listed onNASDAQ: ABEO
- Listed entityAbeona Therapeutics Inc.
- Exchange sectorHealth technology
- ISINUS00289Y2063
- Share price$4.52 (-7.76% on the day) · 2026-10-13
- Market capitalisation$258.5M
- Price to earnings4.3
- EPS (diluted, trailing year)$-1.12
- Volume (last session)1,980,150
Financials of Abeona Therapeutics
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $5.8M | $71.2M | -$85.9M |
| 2024 | -$63.7M | -$61.3M | |
| 2023 | $3.5M | -$54.2M | -$45.0M |
| 2022 | $1.4M | -$39.7M | -$40.7M |
| 2021 | $3.0M | -$84.9M | -$52.9M |
Detailed financial statements for Abeona Therapeutics
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Abeona Therapeutics
5 dated milestones of Abeona Therapeutics across 49 years, from founding to its latest funding, stage changes and deals.
- Founded Abeona Therapeutics is founded.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round.
- Exit Acquired by PlasmaTech Biopharmaceuticals.
- Funding Latest funding round, Post-IPO, of $25.0M.
Competitors of Abeona Therapeutics
Abeona Therapeutics has 3 listed competitors in our database, 3 of them funded. They include Moderna, BridgeBio and Spark Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| bridgebio.com | 2015 | Palo Alto, United States | $434.2M | Therapeutics for genetic diseases are developed through targeted interventions. | ||
| sparktx.com | 2013 | Philadelphia, United States | $82.8M | 822 | Gene therapies for rare diseases including retinal dystrophies are developed. |
Detailed competitors of Abeona Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Abeona Therapeutics
The website of Abeona Therapeutics (abeonatherapeutics.com) receives about 8K visits a month and ranks #2,941,685 among all websites worldwide, #3,924 in Biotechnology and Pharmaceuticals.
- Monthly visits8K
▲ 18.4% vs previous month
- Unique visitors3.4K
per month
- Global rank#2,941,685
among all websites
- Category rank#3,924
Health · Biotechnology and Pharmaceuticals
- Bounce rate38%
- Pages per visit1.8
- Average visit25 sec
- DevicesDesktop 49% · Mobile 51%
Websites whose visitors overlap most with Abeona Therapeutics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| g1therapeutics.com | 100% | 2.8K | #6,603,375 | View details | |
| orexigen.com | 94% | View details | |||
| aerpio.com | 94% | View details | |||
precisiontherapeutics.com | precisiontherapeutics.com | 94% | – | ||
| amicusrx.com | 94% | 20.4K | #1,355,769 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 18 similar websites and full traffic analytics for Abeona Therapeutics
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 18 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Abeona Therapeutics (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Abeona Therapeutics
Complete news archive for Abeona Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Abeona Therapeutics
Abeona Therapeutics was founded in 1974 and raised its 1st funding round 39 years after it was founded.
Abeona Therapeutics is headquartered in New York, United States. It is registered at New York, New York, United States.
Abeona Therapeutics has 136 employees.
Annual revenue of Abeona Therapeutics is $5.82M as on Dec 31, 2025.
Abeona Therapeutics was founded in 1974 and is headquartered in New York, United States. Focus is placed on developing cell and gene therapies to address rare diseases. The lead product candidate, EB-101, is designed for Recessive Dystrophic Epidermolysis Bullosa (RDEB). Additional candidates, such as ABO-102 for Sanfilippo Syndrome and ABO-50X for retinal diseases, are under development. Next-generation AAV capsids are also created for broader gene therapy applications.
Abeona Therapeutics's top competitors include Moderna, Spark Therapeutics and BridgeBio.
Abeona Therapeutics offers pz-cel and ABO-50X.
Yes, Abeona Therapeutics is publicly traded on NASDAQ under the ticker symbol ABEO.
Abeona Therapeutics has 14 investors. Key investors include Perceptive Advisors, Adage Capital Management, Armistice Capital, Deerfield, and EcoR1.
Yes. Abeona Therapeutics was acquired by PlasmaTech Biopharmaceuticals in May 2015.